81. Labhasetwar V, Song C, Humphrey W et al (1998) Arterial uptake of biodegradable
nanoparticles: effect of surface modifications. J Pharm Sci 87:1229–1234
82. Yin Y, Chen DW, Wei XY et al (2007) Lectin-conjugated PLGA nanoparticles loaded with
thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release 123:27–38
83. Jin C, Bai L, Wu H et al (2008) Cellular uptake and radiosensitisation off SR-2508 loaded
PLGA nanoparticles. J Nanopart Res 10:1045
84. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation,
physicochemical characterization and in vitro anti-tumoral activity. J Control Release
83:273–286
85. Danhier F, Lecouturier N, Vroman B et al (2009) Paclitaxel-loaded PEGylated PLGA-based
nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–17
86. Derakhshandeh K, Erfan M, Dadashzadeh S (2007) Encapsulation of 9- nitrocamptothecin, a
novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and
release kinetics. Eur J Pharm Biopharm 66:34–41
87. Gurny R, Peppas NA, Harrington DD et al (1981) Development of biodegradable and
injectable lattices for controlled release potent drugs. Drug Dev Ind Pharm 7:1–25
88. Landry FB, Bazile DV, Spenlehauer G et al (1996) Influence of coating agents on the
degradation of poly(D, L-lactic acid) nanoparticles in model digestive fluids (USP XXII).
Biomaterials 6:195–202
89. Tobio M, Gref R, Sanchez A et al (1998) Stealth PLA-PEG nanoparticles as protein carriers
for nasal administration. Pharm Res 15:270–275
90. Ueda H, Kreuter J (1997) Optimization of the preparation of loperamide-loaded poly (Llactide) nanoparticles by high pressure emulsification solvent evaporation. J Microencapsul
14:593–605
91. Ueda M, Iwara A, Kreuter J (1998) Influence of the preparation methods on the drug release
behavior of loperamide-loaded nanoparticles. J Microencapsul 15:361–372
92. Budhian A, Siegel SJ, Winey KI (2005) Production of haloperidol-loaded PLGA
nanoparticles for extended controlled drug release of haloperidol. J Microencapsul
22:773–785
93. Matsumoto J, Nakada Y, Sakurai K et al (1999) Preparation of nanoparticles consisted of poly
(L-lactide)–poly (ethylene glycol)–poly (L-lactide) and their evaluation in vitro. Int J Pharm
185:93–101
94. Mainardes RM, Gremiao MPD, Brunetti IL et al (2009) Zidovudine-loaded PLA and PLAPEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J Pharm Sci 98:257–267
95. Konan YN, Berton M, Gurny R et al (2003) Enhanced photodynamic activity of meso-tetra
(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm
Sci 18:241–249
96. Perez C, Sanchez A, Putnam D et al (2001) Poly(lactic acid)-poly(ethylene glycol)
nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 75:211–224
97. Xing J, Zhang D, Tan T (2007) Studies on the oridonin-loaded poly (D, L-lactic acid)
nanoparticles in vitro and in vivo. Int J Biol Macromol 40:153–158
98. Sonaje K, Italia JL, Sharma G et al (2007) Development of biodegradable nanoparticles for
oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine
A-induced nephrotoxicity in rats. Pharm Res 24:899–908
99. Sheng Y, Yuan Y, Liu C et al (2009) In vitro macrophage uptake and in vivo biodistribution
of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG
content. J Mater Sci Mater Med 20:1881–1891
100. Cheng FY, Wang SF, Su CH et al (2008) Stabilizer-free poly(lactide-co-glycolide)
nanoparticles for multimodal biomedical probes. Biomaterials 29:2104–2112
101. Yoo HS, Oh JE, Lee KH et al (1999) Biodegradable nanoparticles containing PLGA
conjugate for sustained release. Pharm Res 16:1114–1118
198
S.K. Pandey et al.
nanoparticles: effect of surface modifications. J Pharm Sci 87:1229–1234
82. Yin Y, Chen DW, Wei XY et al (2007) Lectin-conjugated PLGA nanoparticles loaded with
thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release 123:27–38
83. Jin C, Bai L, Wu H et al (2008) Cellular uptake and radiosensitisation off SR-2508 loaded
PLGA nanoparticles. J Nanopart Res 10:1045
84. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation,
physicochemical characterization and in vitro anti-tumoral activity. J Control Release
83:273–286
85. Danhier F, Lecouturier N, Vroman B et al (2009) Paclitaxel-loaded PEGylated PLGA-based
nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–17
86. Derakhshandeh K, Erfan M, Dadashzadeh S (2007) Encapsulation of 9- nitrocamptothecin, a
novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and
release kinetics. Eur J Pharm Biopharm 66:34–41
87. Gurny R, Peppas NA, Harrington DD et al (1981) Development of biodegradable and
injectable lattices for controlled release potent drugs. Drug Dev Ind Pharm 7:1–25
88. Landry FB, Bazile DV, Spenlehauer G et al (1996) Influence of coating agents on the
degradation of poly(D, L-lactic acid) nanoparticles in model digestive fluids (USP XXII).
Biomaterials 6:195–202
89. Tobio M, Gref R, Sanchez A et al (1998) Stealth PLA-PEG nanoparticles as protein carriers
for nasal administration. Pharm Res 15:270–275
90. Ueda H, Kreuter J (1997) Optimization of the preparation of loperamide-loaded poly (Llactide) nanoparticles by high pressure emulsification solvent evaporation. J Microencapsul
14:593–605
91. Ueda M, Iwara A, Kreuter J (1998) Influence of the preparation methods on the drug release
behavior of loperamide-loaded nanoparticles. J Microencapsul 15:361–372
92. Budhian A, Siegel SJ, Winey KI (2005) Production of haloperidol-loaded PLGA
nanoparticles for extended controlled drug release of haloperidol. J Microencapsul
22:773–785
93. Matsumoto J, Nakada Y, Sakurai K et al (1999) Preparation of nanoparticles consisted of poly
(L-lactide)–poly (ethylene glycol)–poly (L-lactide) and their evaluation in vitro. Int J Pharm
185:93–101
94. Mainardes RM, Gremiao MPD, Brunetti IL et al (2009) Zidovudine-loaded PLA and PLAPEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J Pharm Sci 98:257–267
95. Konan YN, Berton M, Gurny R et al (2003) Enhanced photodynamic activity of meso-tetra
(4-hydroxyphenyl)porphyrin by incorporation into sub-200 nm nanoparticles. Eur J Pharm
Sci 18:241–249
96. Perez C, Sanchez A, Putnam D et al (2001) Poly(lactic acid)-poly(ethylene glycol)
nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 75:211–224
97. Xing J, Zhang D, Tan T (2007) Studies on the oridonin-loaded poly (D, L-lactic acid)
nanoparticles in vitro and in vivo. Int J Biol Macromol 40:153–158
98. Sonaje K, Italia JL, Sharma G et al (2007) Development of biodegradable nanoparticles for
oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine
A-induced nephrotoxicity in rats. Pharm Res 24:899–908
99. Sheng Y, Yuan Y, Liu C et al (2009) In vitro macrophage uptake and in vivo biodistribution
of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG
content. J Mater Sci Mater Med 20:1881–1891
100. Cheng FY, Wang SF, Su CH et al (2008) Stabilizer-free poly(lactide-co-glycolide)
nanoparticles for multimodal biomedical probes. Biomaterials 29:2104–2112
101. Yoo HS, Oh JE, Lee KH et al (1999) Biodegradable nanoparticles containing PLGA
conjugate for sustained release. Pharm Res 16:1114–1118
198
S.K. Pandey et al.